Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.78)
# 2,906
Out of 4,818 analysts
62
Total ratings
44.19%
Success rate
-4.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $59.28 | +11.34% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $37.99 | -42.09% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $3.65 | +310.96% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $18.64 | +146.78% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $10.44 | +72.50% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.41 | +254.61% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $4.86 | +167.77% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $29.18 | -4.04% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $40.50 | +28.40% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.68 | +3,709.52% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $0.82 | +2,690.92% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.12 | +1,775.00% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $2.80 | +400.00% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $28.90 | -72.31% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.26 | +5,983.65% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $59.28
Upside: +11.34%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $37.99
Upside: -42.09%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $3.65
Upside: +310.96%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $18.64
Upside: +146.78%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $10.44
Upside: +72.50%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.41
Upside: +254.61%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $4.86
Upside: +167.77%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $29.18
Upside: -4.04%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $40.50
Upside: +28.40%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.68
Upside: +3,709.52%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $0.82
Upside: +2,690.92%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.12
Upside: +1,775.00%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $2.80
Upside: +400.00%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $28.90
Upside: -72.31%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.26
Upside: +5,983.65%